Search research articles
Contact Us
Filters
Showing results (251-260 of 301) with videos related to
Page
of 31
Sort By:
Cancer Research
|
September 1, 1990
In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors
L Rivoltini, C Gambacorti-Passerini, M Squadrelli-Saraceno, et al.
European Journal of Immunology
|
January 1, 1995
CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes
A Martinotti, A Stoppacciaro, M Vagliani, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
May 30, 1998
Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanoma
C Clemente, S Rao, R Lupetti, et al.
Advances in Experimental Medicine and Biology
|
February 23, 1999
Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogeneic melanoma cells
F Belli, L Mascheroni, G Gallino, et al.
Melanoma Research
|
November 1, 1992
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study
F Belli, F Arienti, L Rivoltini, et al.
Cancer Research
|
January 4, 1998
Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors
R Mortarini, A Anichini, M Di Nicola, et al.
Cancer Research
|
September 15, 1989
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation
C Gambacorti-Passerini, L Rivoltini, M Radrizzani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 1996
Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients
S Dermime, C Bertazzoli, E Marchesi, et al.
The Journal of Experimental Medicine
|
September 22, 1998
Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
R Lupetti, P Pisarra, A Verrecchia, et al.
International Journal of Cancer
|
December 11, 1995
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
M Marchand, P Weynants, E Rankin, et al.
Page
of 31
Search research articles
Search
Showing results (251-260 of 301) with videos related to
Sort By:
Page
of 31
Cancer Research
|
September 1, 1990
In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors
L Rivoltini, C Gambacorti-Passerini, M Squadrelli-Saraceno, et al.
European Journal of Immunology
|
January 1, 1995
CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes
A Martinotti, A Stoppacciaro, M Vagliani, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
May 30, 1998
Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanoma
C Clemente, S Rao, R Lupetti, et al.
Advances in Experimental Medicine and Biology
|
February 23, 1999
Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogeneic melanoma cells
F Belli, L Mascheroni, G Gallino, et al.
Melanoma Research
|
November 1, 1992
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study
F Belli, F Arienti, L Rivoltini, et al.
Cancer Research
|
January 4, 1998
Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors
R Mortarini, A Anichini, M Di Nicola, et al.
Cancer Research
|
September 15, 1989
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation
C Gambacorti-Passerini, L Rivoltini, M Radrizzani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 1996
Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients
S Dermime, C Bertazzoli, E Marchesi, et al.
The Journal of Experimental Medicine
|
September 22, 1998
Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
R Lupetti, P Pisarra, A Verrecchia, et al.
International Journal of Cancer
|
December 11, 1995
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
M Marchand, P Weynants, E Rankin, et al.
Page
of 31